While the positive findings with the use of GLP‐1 receptor agonists in patients with COVID‐19 and concurrent diabetes are encouraging, clinicians are recommended not to prescribe GLP‐1 receptor agonists solely for the purpose of improving the prognosis of this population of patients before the publication of more solid evidence from randomized controlled trials. Here, GLP1R is linked to diabetes mellitus.